ReviewMedChemComm2018
Chemical probes of Skp2-mediated p27 ubiquitylation and degradation.
Review in MedChemComm, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- Structure-Based Discovery of Fumiquinazolines as Skp2-Cks1 Protein-Protein Interaction Disruptors: Mechanistic Computational Insights and Experimental Validation.ChemMedChem · 2026Article
- Structure-based discovery of diphenylpyrazines as disruptors of the Skp2-Cks1 protein-protein interaction: computational insights and biochemical validation.Journal of computer-aided molecular design · 2026Article
- A pan-cancer analysis revealedPrecision clinical medicine · 2025Article
- Distinct outcomes from targeted perturbations of the multi-subunit SCFCommunications biology · 2025Article
- Emerging approaches to CDK inhibitor development, a structural perspective.RSC chemical biology · 2023Article
- Targeting the untargetable: RB1-deficient tumours are vulnerable to Skp2 ubiquitin ligase inhibition.British journal of cancer · 2022Review
- FBXO17 Inhibits the Wnt/β-Catenin Pathway and Proliferation of Ishikawa Cells.International journal of medical sciences · 2022Article
- Phytochemical library screening reveals betulinic acid as a novel Skp2-SCF E3 ligase inhibitor in non-small cell lung cancer.Cancer science · 2021Article
- Blocking the Spinal Fbxo3/CARM1/KNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Article
- Ubiquitin-proteasome system-targeted therapy for uveal melanoma: what is the evidence?Acta pharmacologica Sinica · 2021Review
- Retinoblastoma: Etiology, Modeling, and Treatment.Cancers · 2020Review
- Targeted Inhibition of the E3 Ligase SCFCancer research · 2020Article
- SKP2 targeted inhibition suppresses human uveal melanoma progression by blocking ubiquitylation of p27.OncoTargets and therapy · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Skp2 is a member of the F-box family of proteins that serve as substrate-specific adaptors in Skp1-CUL1-ROC1-F-box (SCF) E3 ubiquitin ligases. Skp2 (Fbxl1) directly binds to the tumor suppressor p27 in the context of the SCF
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.